Big discounting Methyl 2-Hydroxy-3-Methoxy-3 3-Diphenylpropanoate - 3-Benzyl-6-Bromo-2-Chloroquinoline CAS 654655-68-2 Bedaquiline Fumarate Intermediate Purity ≥99.0% (HPLC) Factory – Ruifu

Short Description:

Product Detail

Product Tags

Feedback (2)

Well-run equipment, specialist income crew, and better after-sales services; We're also a unified major family, anyone stay with the organization value "unification, determination, tolerance" for 125995-13-3, Carfilzomib CAS 868540-17-4, Molecular Formula C20H20O9, We believe you will be satisfied with our reasonable price, high quality products and fast delivery. We sincerely hope you can give us an opportunity to serve you and be your best partner!

Big discounting Methyl 2-Hydroxy-3-Methoxy-3 3-Diphenylpropanoate - 3-Benzyl-6-Bromo-2-Chloroquinoline CAS 654655-68-2 Bedaquiline Fumarate Intermediate Purity ≥99.0% (HPLC) Factory – Ruifu Detail:

Commercial Supply Bedaquiline Related Intermediates:
3-Benzyl-6-Bbromo-2-Mmethoxyquinoline CAS: 654655-69-3
3-Benzyl-6-Bromo-2-Chloroquinoline CAS: 654655-68-2
3-(Dimethylamino)-1-(Naphthalen-1-yl)propan-1-one Hydrochloride CAS: 5409-58-5
Bedaquiline Fumarate CAS: 845533-86-0

Chemical Name	3-Benzyl-6-Bromo-2-Chloroquinoline
Synonyms	6-Bromo-2-Chloro-3-(Phenylmethyl)quinoline; Bedaquiline Impurity B; Bedaquiline Fumarate Impurity 5
CAS Number	654655-68-2
CAT Number	RF-PI107
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C₁₆H₁₁BrClN
Molecular Weight	332.62
Brand	Ruifu Chemical

Item	Specifications
Appearance	White to Off-White or Light Yellow Powder
Purity / Analysis Method	≥99.0% (HPLC)
Melting Point	100.0~120.0℃
Moisture (K.F)	≤0.50%
Residue on ignition	≤0.50%
Total Impurities	≤1.00%
Test Standard	Enterprise Standard
Usage	Intermediate of Bedaquiline Fumarate (CAS: 845533-86-0)

121

3-Benzyl-6-bromo-2-chloroquinoline (CAS: 654655-68-2) is a main intermediate of Bedaquiline Fumarate (CAS: 845533-86-0). Bedaquiline Fumarate is a diarylquinone drug developed by Janssen Pharmaceutical. The drug, which was approved in 2012 for the treatment of multidrug-resistant tuberculosis (MDR-TB), was developed in partnership with Johnson & Johnson and represents the first new tuberculosis therapy approved in over four decades. Bedaquiline Fumarate used in combination therapy for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of th mycobacteria.

Product detail pictures:

Related Product Guide:

The really abundant projects management experiences and 1 to just one provider model make the high importance of business enterprise communication and our easy understanding of your expectations for Big discounting Methyl 2-Hydroxy-3-Methoxy-3 3-Diphenylpropanoate - 3-Benzyl-6-Bromo-2-Chloroquinoline CAS 654655-68-2 Bedaquiline Fumarate Intermediate Purity ≥99.0% (HPLC) Factory – Ruifu , The product will supply to all over the world, such as: Gambia, Ottawa, Karachi, What You Need Is What We Pursue.We are sure our products will bring you first class quality.And now sincerely hope to promote partner friendship with you from all over the world. Let's joint hands to cooperate with mutual benefits!